Midostaurin (Rydapt) for aggressive systemic mastocytosis

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Regimen in use at


FDA-recommended dose
Study Evidence Efficacy
Gotlib et al. 2016 (CPKC412D2201) Phase 2 (RT) ORR: 60% (95% CI 49 to 70)
Chandesris et al. 2016 (CEREMAST) Phase 2 (RT)

CPKC412D2201 included untreated and previously untreated patients.


28-day cycles


  1. CPKC412D2201: Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P, Reiter A. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2530-41. link to original article contains dosing details in manuscript link to supplementary appendix PubMed Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia (NCT00233454) at ClinicalTrials.gov
  2. CEREMAST: Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, Frenzel L, Cherquaoui Z, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jeandel PY, Ranta D, Gressin R, Chantepie S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O; CEREMAST Study Group. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2605-7. link to original article PubMed